Founded in 2020, Marginum is revolutionising oncological surgery.
With the developed tissue detection technology for surgery, Marginum aims to make a real impact by helping millions of patients and surgical professionals around the globe.
Accurate identification of tumours and distinguishing them from healthy tissues during cancer surgery is a critical challenge surgeons face. With an ageing population and the projected 55 % increase in global cancer incidence by 2040, there will be over 20 million cancer patients each year in need of surgery.
Marginum’s minimally invasive tissue monitoring technology empowers surgeons with precise information about the presence and extent of fluorescent tissue without compromising pre-existent surgical workflow. The patented solution aims to assist surgeons to perform more accurate and targeted resections, reducing tumour recurrence and the need for reoperations while improving patient safety and surgical outcomes.
“Redstone is a European venture capital firm following selected investment strategies. Redstone’s North Karelia Growth Fund invests in companies that build upon regional strengths in technology and life sciences. Marginum’s promising technology enables positive societal change with safer and more accurate surgery.”
– Kaj Hagros
Managing Partner, Redstone Nordics
“Nostetta Ventures invests in early-stage companies with groundbreaking innovations and exceptional teams within North Savo region. Marginum’s industry-shaping technology has its origins in the University of Eastern Finland, and the team excels in surgical technology, clinical research, and rapid advancement of the company’s technology.”
– Noora Tuikka
CEO, Nostetta Ventures
“Almaral invests in early-stage biotech and life science companies with technologies that can significantly enhance healthcare professionals' ability to deliver services with improved efficiency, quality, or significantly reduced costs, without compromising the quality of care. Marginum enables fundamental changes in the surgical market and contributes to solving a global health issue.”
– Dr. Maria Severina
Founder & CEO, Almaral
"Marginum is developing the next-generation fluorescence-based optical tissue monitoring technology to improve surgical performance and cost-effectiveness. There is an urgent need to decrease healthcare costs and the number of reoperations and complications.
The MARGINUM® tissue monitoring solution assists in safe and efficient tumour detection from surgical suction waste. The surgeon will be notified in near real-time if fluorescence is present in the resected tissue. This non-invasive approach – easily integrated into the current surgical workflow – aims to assist in precise detection of tumour cells leading to minimal damage to healthy tissues.
Our dedicated multidisciplinary team works closely with clinical, academic and industrial leaders to ensure our solutions’ seamless clinical compatibility according to clinicians’ preferences."
Samu Lehtonen MD
CEO & Co-Founder
We aim to achieve this by developing a groundbreaking fluorescence-based tissue detection system that enables efficient and safe monitoring of tissues during cancer surgery.
Unlike any other solution, Marginum allows precise quantitative detection of fluorescent tissue from surgical suction waste without compromising workflow. With our technology we hope to fulfil our vision to radically improve surgical outcomes and patient welfare, welcoming a data-driven shift in surgical approach.
Keep up with the insights into Marginum’s pioneering advancements and transformative investment opportunities.
26.2.2026 | Neuro-Oncology Advances
A first-in-human study shows that HIVEN®-based aspirate tissue monitoring provides nearly 5 times more fluorescence information than visual guidance alone.
17.12.2025 | THE FINNISH MEDICAL FOUNDATION
CEO Samu Lehtonen has been nominated for the prestigious Pohjola Medical Innovation Award in recognition of the Marginum team’s scientific contributions.
3.11.2025 | BUSINESS FINLAND
Marginum has been selected for the prestigious Young Innovative Companies (YIC) program, a recognition reserved for Finland’s most promising startups.
20.10.2025 | MARGINUM NEWS
Marginum has completed the HIVEN® usability assessment at the University of Illinois College of Medicine Surgical Innovation and Training Laboratory.
15.10.2025 | Marginum News
Thomy F.E., d.o.o., one of Slovenia’s leading distributors of advanced medical and surgical technologies, has formed a strategic partnership with Marginum.
3.10.2025 | Redacción Médica
MBA SURGICAL EMPOWERMENT, a leading Spanish distributor in the medical-surgical technology sector, has partnered with Marginum.